Squarepoint
LYEL icon

Squarepoint’s Lyell Immunopharma LYEL Stock Holding History

Squarepoint’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$387K Buy
+19,294
New +$451K ﹤0.01% 3514
2025
Q2 		– Sell
-9,916
Closed -$107K – 4819
2025
Q1 		$107K Buy
+9,916
New +$121K ﹤0.01% 4202
2024
Q4 		– Sell
-6,775
Closed -$187K – 5314
2024
Q3 		$187K Buy
+6,775
New +$199K ﹤0.01% 3708
2024
Q2 		– Sell
-3,685
Closed -$164K – 4412
2024
Q1 		$164K Sell
3,685
-11,554
-76% -$495K ﹤0.01% 3676
2023
Q4 		$591K Buy
15,239
+12,542
+465% +$452K ﹤0.01% 2885
2023
Q3 		$79.3K Buy
+2,697
New +$128K ﹤0.01% 3591
2021
Q3 		– Sell
-2,549
Closed -$828K – 3208
2021
Q2 		$828K Buy
+2,549
New +$836K ﹤0.01% 1775

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return